Skip to main content
    A

    AstraZeneca PLC (AZN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $184.45
    +0.07 (+0.04%)

    Market Cap: $286.07B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AstraZeneca PLC (AZN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect AstraZeneca (AZN) to earn $10.12 per share in the fiscal year ending Dec 31, 2026, on revenue of $63.38B. Of 12 analysts, 9 rate the stock Buy or Strong Buy, 2 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.17, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.

    RatingAnalystsShare
    Strong Buy216.7%
    Buy758.3%
    Hold216.7%
    Sell18.3%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 11.9% and revenue estimates rise 6.3%.

    Fiscal year ending Dec 31, 2026
    $10.12
    EPS consensus, revenue $63.38B
    Fiscal year ending Dec 31, 2027
    $11.32
    EPS consensus, revenue $67.39B
    Fiscal year ending Dec 31, 2028
    $12.95
    EPS consensus, revenue $72.12B

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$10.12$10.08 to $10.162$63.38B$61.91B to $64.21B25
    Dec 31, 2027$11.32$10.83 to $11.843$67.39B$65.24B to $68.92B25
    Dec 31, 2028$12.95$9.56 to $14.409$72.12B$71.84B to $72.41B21

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.43$2.09 to $2.7218$17.18B$15.82B to $18.21B19

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202711

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.3% from $10.09.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$10.12$10.05$10.07$10.05$10.09+0.3%
    Fiscal year ending Dec 31, 2027$11.32$11.34$11.57$11.36$11.58-2.3%

    Frequently Asked Questions About AZN

    What is the AZN stock forecast?

    Consensus analyst estimates put AstraZeneca's EPS at $10.12 for the fiscal year ending Dec 31, 2026, on revenue of $63.38B. The consensus rating from 12 analysts is Buy.

    How do analysts rate AZN stock?

    Of 12 analysts covering AstraZeneca, 2 rate it Strong Buy, 7 Buy, 2 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from AZN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $10.12, with estimates from $10.08 to $10.16 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.32, with estimates from $10.83 to $11.84 from 3 analysts.

    What revenue do analysts expect from AstraZeneca next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $63.38B, with estimates from $61.91B to $64.21B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $67.39B, with estimates from $65.24B to $68.92B.

    How many analysts cover AZN?

    12 analysts rate AstraZeneca stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.